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Cervical cancer is a progressive disease with an onset of
one to two decades on average. During the productive replica-
tion stage, the Human papillomavirus (HPV) genome is main-
tained episomally in the infected cervical epithelium and early
gene products, including E5, are expressed. Therefore, E5 has
a potential to contribute to the HPV-associated carcinogenic
process. In invasive malignancies, the HPV genomes are com-
monly integrated into the host genome, and E6 and E7 genes
remain intact. However, the E5 is lost or, if present, under-ex-
pressed as compared with the E6 and E7 proteins. This sug-
gests that E5 may play a critical role in the genesis of cervical
cancer but less of a role in its persistence or progression. In
the initiation of neoplasia and the premalignant stage, there
are fewer malignant cells than in the invasive malignancies.
Moreover, cells in the invasive malignant stage are found to
have a very low level of MHC class I and II, which could
hamper the presentation of the antigen and lead to a decreased
immune response. Since the E5 protein is likely to play a role
during the early tumorigenesis stage, a therapeutic vaccine to
target and eliminate the E5-expressing cells may be a good
strategy to prevent premalignant lesions from progressing
toward invasive cervical cancers. This paper provides an
overview of HPV-induced cervical carcinogenesis and
strategies for designing prophylactic and therapeutic vaccines
to prevent and cure the cervical cancer. In particular, focus
will be on the rationale of targeting the E5 protein to develop
therapeutic vaccines.
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INTRODUCTION
Cervical cancer and precancerous cervical le-
sions are a major problem in women's health.
Clinical, molecular and epidemiological investiga-
tions have identified HPV as the major cause of
cervical cancer and cervical dysplasia. Virtually all
cervical cancers contain high-risk HPV genes,
most commonly types 16, 18, 31, and 45.
1 HPVs
infect epithelial cells of skin and mucosal sur-
faces.
2 To date, at least 80 distinct types of HPV
have been isolated from various human tissue
biopsies. A subset of these HPVs is sexually trans-
mitted and causes a spectrum of diseases in the
male and female genital tract.
3 These HPVs can be
categorized according to their potential to cause
malignancy as low risk, intermediate risk or high
risk. HPV types 6 (HPV-6) and 11 (HPV-11), for
example, are associated with low-risk disease,
such as genital warts. On the contrary, high-risk
HPVs, such as HPV-16, -18, -31, -33 and -45, are
associated with high-grade intraepithelial lesions
and invasive cancer. Among the high-risk strains,
HPV-16 and -18 are the most closely associated
with cervical carcinoma. HPV-16 DNA has been
found in more than 50% of squamous cell car-
cinomas, while HPV-18 DNA has been found in
more than 50% of adenocarcinomas.
2
HPVs comprise a large family of double-
stranded DNA (ds DNA) tumor viruses whose
genome is organized into three regions: early
genes (E1 to E7), late genes (L1 and L2) and the
non-coding long control region (LCR) containing
a variety of cis elements
4 which regulate viral
replication and gene expression (Fig. 1). The LCR
possesses numerous binding sites for many re-
pressors and activators of transcription. Both E1
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and E2 have been shown to be essential for the
replication of the origin of HPV. The E1 and E2
encode proteins which are essential for extra-
chromosomal DNA replication and completion of
the viral life cycle. The E2 is a DNA binding
transcription factor interacting with ACCN6GGT
motifs in the viral LCR.
5 The E2 encodes two
proteins which inhibit and activate the early
region, respectively. A hallmark of HPV-asso-
ciated cervical carcinoma is the loss of this E2
protein expression.
6 In addition to modulating
viral gene expression, the E2 proteins are asso-
ciated with the viral helicase E1. This interaction
is necessary for efficient recognition of the origin
and viral genome replication.
7,8 An E4 protein is
expressed in the later stages of infection after
completion of the virion assembly. The E4 is
considered to play an important role in the
maturation and replication of the virus.
9 The E4
protein also induces the collapse of the cyto-
plasmic cytokeratin network in human keratino-
cytes. This situation may facilitate the release of
virions from infected cells.
10 Expression of the
viral E1-E4 proteins are lost during a malignant
progression, but not in premalignant lesions.
Expression of HPV-16 E1-E4 in cell cultures is
high and causes cell cycle arrest at the G2 phase
by sequestration of cyclin-dependent kinase 1
(Cdk1)/cyclin B1 in the cytokeratin network.
This prevents the accumulation of active Cdk1/
cyclin B1 complexes in the nucleus resulting in
inhibition of mitosis. In another report, HPV-16
E1-E4 mutants (T22A, T23A) which do not bind
cyclin B1 or alter its intracellular location failed
to induce G2 arrest.
11 Meanwhile, an E5 open
reading frame (ORF), is often deleted in cervical
carcinoma cells. This indicates that it may not be
essential in maintaining the malignant transfor-
mation of the infected cells.
12 The E5 interacts
with various transmembrane proteins such as
receptors of the epidermal growth factor (EGF),
13
platelet-derived growth factor (PDGF ) β β
14 and
colony stimulating factor (CSF). The E5 protein
has transforming activity in HPV-16 infected
cells. In the protein-encoding regions, E6 and E7
ORFs are considered to play major roles in HPV
pathogenesis. These two genes encode for onco-
proteins allowing replication of the virus, im-
mortalization and transformation of the host
cells.
15-18 Late region units, L1 and L2, encode for
viral capsid proteins during the late stages of
virion assembly (Table 1). The protein encoded
by L1 is highly conserved among different papil-
lomavirus species. Therefore, antibodies against
the Bovine Papillomavirus (BPV) have been used
to identify HPV capsid proteins in human
tissues. The minor capsid protein encoded by L2
has more sequence variations than that of the L1
protein; hence, antibodies against the L2 protein
have been a source of antigens for specific types
of HPV antibodies.
19
Fig. 1. Schematic diagram for linear HPV genome structure. The early (E) and late (L) genes, as well as the LCR, are
shown. The poly A+ signals (PA) for the early and late mRNA are shown.Therapeutic Vaccine Targeting HPV Type 16 E5 Protein
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THE ROLE OF THE HUMAN PAPILLOMA-
VIRUS E5 IN CERVICAL CARCINOGENESIS
HPV-16 E5 protein
The HPV-16 E5 protein is a small (84 aa) hydro-
phobic membrane protein located just down-
stream of the E2 open reading frame.
20 The gene
is not well conserved at the DNA level among
HPVs or animal viruses, although there is con-
servation of some properties, as the proteins are
all highly hydrophobic and membrane- bound.
20
The E5 proteins from both animal and human
sources can transform mammalian cells with var-
ying degrees of efficiency. The protein is mem-
brane-bound and distributed predominantly in
the endoplasmic reticulum, the Golgi and the
cytoplasmic membrane.
21 The E5 protein is hydro-
phobic and presents as a dimer even in reducing
conditions. The E5 protein is difficult to detect
because the protein is insoluble and generation of
good antibodies against E5 are limited. Antigenic
peptide antibodies against the N-and C-terminal
have been produced successfully. Fragment dele-
tion of the E5 ORF in cervical carcinoma cells
indicates that E5 does not play an essential role
in maintaining the malignant phenotype. This
allows the presence of the E5 protein to be used
as a prognostic predictor marker.
22 The HPV-16 E5
protein contributes to cellular transformation by
increasing a mitogenic stimulus from growth fac-
tor receptors to the nucleus. In this transformation
mechanism, the E5 protein co-localizes with an
anti-apoptotic Bcl-2 protein.
23 The E5 protein of
BPV impairs the synthesis and stability of the
major histocompatibility complex (MHC) class I
and prevents their transport to the cell surface
due to retention in the Golgi apparatus. The HPV-
16 E5 protein also causes the retention of MHC
(HLA) class I in the Golgi apparatus and impedes
their transport to the cell surface, which is rescued
by treatment with interferon. Unlike BPV E5,
HPV-16 E5 does not affect the synthesis of HLA
class I heavy chains or the expression of the
transporter associated with antigen presentation
(TAP). These results show that down-regulation of
the surface MHC class I molecules is common to
both BPV and HPV E5 proteins.
Table 1. Function of HPV Gene Products
Protein Function [Reference]
E1 DNA helicase activity, DNA-dependent ATP-binding, ATPase activity, Role in replication and replication
repressor [5,9]
E2 Regulator of viral transcription and replication, control of early region viral gene expression, necessary for
efficient viral DNA replication together with E1 [8,9,10]
E5 Transforming activity , Presumably stimulates benign cell proliferation in vivo but might have a role in the
innitiator of carcinogenesis. Downregulation MHC class expression [14,15,16]
E6 Role in transformation process together with E7, Transcriptional activation properties E6 of high-risk HPVs
inactivates p53 by including its degradation, Together with E7 provides a cellular enviroment for viral DNA
replication [17,18,19,20]
E7 Transactivating properties similar to the adenovirus E2 promoter, induced DNA synthesis in quiescent cells,,
role in rodent cell transformation in co-operation with an activated ras oncogene. E7 binds to the hypopho-
sphorylated from of retinoblastoma protein (pRB) resulting in its functional inactivation permitting cell
progression to S phase of cell cycle. E7 proteins from the low-risk HPV type 6 and 11 bind less efficiently
than the E7 protein from high-risk HPVs (type 16 and 18) [17,18,19]
E4 Expressed as a late gene primarily in differentiating epithelium, role in productive infection associated with
the keratin cytoskeleton of cultured epithelial cells, role in viral egress, G2 cell cycle arrest [12,13]
L1 Major capsid protein
L2 Major capsid proteinSang-Woo Kim and Joo-Sung Yang
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Transformation and immortalization properties
There are well recognized cellular targets for
the E5 protein: PDGF -R and the 16-kDa subunit β
of the vacuolar H
+-ATPase.
24 The original E5-
receptor interaction was described for BPV type 1
E5. The E5 viral protein was found to stabilize an
epidermal growth factor receptor (EGFR) in the
presence of the ligand. The ligand-receptor com-
plex was not broken down and a hyper-stimul-
ating signal was observed.
25 The BPV-1 E5 was
found in a complex with the PDGF receptor β
(PDGF -R) β
26 and could activate PDGF -R in the β
absence of the ligand PDGF . The E5-PDGF -R β β
interaction occurs during the natural history of
bovine urinary bladder tumors, suggesting an im-
portant role for E5 in carcinogenesis.
14 However,
the PDGF -R is not found on human keratino β -
cytes. The EGFR is the major receptor in keratino-
cytes. The HPV E5 proteins appear to affect the
activity of growth factor receptors and their
signaling pathways. The interaction of E5 proteins
with a subunit of vacuolar adenosine triphos-
phatase (ATPase) may contribute to a transforma-
tion.
12 In order to elucidate this E5 oncogenic
activity, the significance of the interaction between
E5 and EGFR has been studied. Enhanced activa-
tion of the signaling cascade by E5 is EGFR-
dependent. In the presence of the E5 protein, the
EGFR number is increased.
13 This effect is due to
an impaired down-regulation of receptors and
recycling of those to the cell membrane in E5-
expressing cells. An ubiquitination of the acti-
vated EGFR plays a role in this down-regulation
(Fig. 2). A c-Cbl is a ubiquitin ligase which asso-
ciates with the activated EGFR and targets it for
degradation. HPV-16 E5 may, at least in part,
upregulate EGFR-mediated signal transduction by
inhibiting the interaction of the c-Cbl with the
EGFR, then decreasing the c-Cbl-mediated degra-
dation of the EGFR.
27 Moreover, this enhanced
receptor recycling is mediated by E5 binding to a
16-kD subunit of the ATPase proton pump located
in the endosomal membrane. This binding can be
Fig. 2. HPV E5 protein facilitates EGFR recycling mediated by E5-ATPase binding. In normal cells, low pH in the
endosome degrades the activated EGF receptor, thereby attenuating signaling. The vacuolar ATPase maintains the low
pH required for receptor degradation. In the E5-transformed cells, the E5 protein binds directly to the vacuolar ATPase
and inhibits its activity. This impairs endosome acidification and EGF receptor degradation, resulting in increased
recycling of the receptor to the cell surface and enhanced receptor signaling. Therefore, cell proliferation is induced.
(Modified from DiMaio D and Mattoon D, Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene
2001;20:7866-73.)Therapeutic Vaccine Targeting HPV Type 16 E5 Protein
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demonstrated in vitro.
27 In vivo data also revealed
the E5 protein predominantly existing in the
cytoplasmic membrane region of E5-transfected
cells and the HPV-16 infected tissue, with the E5
protein binding to the 16-kD molecule. In contrast,
one study reported that EGF treatment increased
EGFR phosphorylation instead of the receptor
number in E5-expressing cells.
26 This result sug-
gested that E5 could form a complex with EGFR
to induce the phosphorylation of EGFR. However,
other researchers could not demonstrate an E5-
EGFR complex-induced signaling pathway. An
EGFR-independent pathway has also been pro-
posed to function in the E5 protein-activated
signaling cascade. The HPV-16 E5 modulates the
sorbital-dependent activation of mitogen-activated
protein (MAP) kinase p38 and ERK1/2 in human
keratinocytes through an EGF-independent mech-
anism.
28 Taken together, E5-activating signaling
cascades appear to be mediated via either a recep-
tor-dependent or receptor-independent pathway.
The HPV-16 E5 can transform immortalized
rodent fibroblasts and the frequency of transfor-
mation is increased in the presence of EGF but not
PDGF. The HPV-16 E5 protein is unable to form
transformed foci on cell monolayers and therefore
is considered to have only moderate transforming
activity, unlike the BPV-1 E5 gene, which can
form transformed foci on rodent monolayer cul-
tures. It should be remembered that the BPV-1 E5
protein is the major transforming protein, unlike
HPVs' E5. The HPV-16 E5 protein is unable to
immortalize primary human keratinocytes,
29
however, the E5 induces cell proliferation and
extends the life span of cells predisposed with
activated EFGR. In addition, the full length HPV-
16 genome with a premature stop codon in the E5
gene is only able to immortalize keratinocytes at
10% of the frequency of the wild type genome,
suggesting that E5 plays a complementary role in
the immortalization process.
30
E5 and signal transduction
The HPV-16 E5 protein can activate EGFR,
which in turn can initiate diverse biochemical
events that ultimately render the over-expression
of a variety of proto-oncogenes.
31 The HPV-16 E5
protein might activate MAP kinases via two
different pathways, one for the protein kinase C
(PKC-dependent), the other for the receptor
tyrosine-kinase mediated (PKC-independent) path-
way.
28 The E5 could stimulate the nuclear onco-
genes, such as c-jun, junB and c-fos.
32 The c-jun
nuclear oncogene is activated by HPV-16 E5 via
PKC and ras-dependent pathways that transmit
signals to the nucleus. The E5 activation of c-jun
is through an activator protein-1 (AP-1) binding
site and the E5-activation of c-fos is via a nuclear
factor-1 (NF-1) binding site in the nucleus. Since
several binding sites of AP-1 and NF-1 are located
in the regulatory region of the HPV-16 DNA,
these transcription factors can activate the
enhancer of HPV-16, and the E5 may potentiate
viral gene expression via the activation of AP-1
and NF-1.
20 Thus, the E5 protein transactivates
viral genes and thereby increases the viral E6/E7
gene expression and regulates E7-mediated cell
transformation. In conclusion, the E5 protein may
play a role in cell transformation by regulating the
expression of other cellular and viral genes. The
E5 protein could down-regulate the expression of
the p21
(WafI/SdiI/CipI) tumor suppressor gene in NIH
3T3 cells and in immortalized human keratino-
cytes,
33 which could promote cell proliferation.
This observation also suggests a role for E5 in
augmenting or supplementing the function of E6
and E7 during immortalization of human genital
keratinocytes in the course of primary infection.
Colony numbers were higher in primary
keratinocytes infected with the full-length HPV-16
genome than in those with mutated E5 gene-con-
taining HPV-16 genomes. This finding demon-
strates that the E5 protein can act in cis to increase
the efficiency of cellular immortalization by the
E6/E7 protein. In addition, mutations in E7 of the
HPV-16 genome, which inhibits the binding of
pRb, could not abrogate HPV-16-induced immor-
talization of primary human keratinocytes. More-
over, intradermal injection of cottontail rabbit
papillomavirus DNA, which has mutations in the
E7 gene sequences critical for the binding of pRb,
could still induce papilloma formation in rabbits.
Hence, the repression of the p21 gene by the E5
protein may complement the altered pRb binding
activity of the mutated E7. Moreover, suppression
of the p21 gene by E5 may facilitate the activation
of Cdk4-cyclin D complexes, which are known toSang-Woo Kim and Joo-Sung Yang
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phosphorylate pRb and inactivate the Rb-check-
point control. It remains uncertain whether the E5
can supplement the E6 transformation activity.
The E6 protein targets the tumor suppressor pro-
tein p53, resulting in p53 degradation and con-
tributing to malignant transformation. Although
p53 can activate the gene expression of p21, it is
unclear whether repression of the p21 gene ex-
pression by HPV is in a p53-dependent manner.
34
Therefore, investigations are still necessary to
decipher the complicated networks existing
among E5, E6, p53, and p21.
ONCOGENESIS INDUCED BY HPV-16
In cervical neoplasia, high-risk HPV infection
occurs predominantly in either basal or parabasal
cells of the transformation zone epithelium.
35 The
HPV virion infects basal cells of the stratified
mucosal epithelium at the junction between the
vagina ectocervix (Fig. 3). Limited viral replication
is accompanied by expression of the early proteins
E1 and E2 in the basal layer. In more distal layers,
E6 and E7 proteins are expressed. These proteins
promote cell proliferation and delay differentia-
tion. As infected cells differentiate into squamous
cells, the E4 protein and the late proteins L1 and
L2 are expressed. The viral capsid is shed into the
genital tract within desquamated epithelial cells.
The E5 protein is likely to play a role during the
premalignant stage.
3 Rarely is the circular HPVs
genome linearized randomly and integrated into
a host genome. During the HPV DNA integration,
the viral genome usually breaks in the E1/E2
region, resulting in the loss of E1 and E2 regions.
The E2 encodes proteins which inhibit the tran-
scription of the E6 and E7 regions. The loss of E2
leads to uncontrolled and increased expression of
the E6 and E7 oncogenic proteins. The increased
expression of E6 and E7 meanwhile has led to the
malignant transformation of host cells and to
Fig. 3. Infection of HPV to target cell and early gene expression in basal layer. In the virion productive stage, the early
proteins E1 and E2 are expressed. In the more distal layer, the E5, E6, and E7 proteins are expressed. These proteins
promote cell proliferation and delay differentiation. As infected cells differentiate into squamous cells, the E4 protein and
the late proteins L1 and L2 are expressed. The viral capsid is shed into the genital tract within desquamated epithelial
cells. In the malignant stage, the HPV oncogenes are linearized randomly and integrated into the host cell genome. At
that time, the host cell is induced into the premalignant stage by the E5 protein. Viral DNA integration leads to
uncontrolled viral oncoprotein (E6, E7) production and host cell transformation.Therapeutic Vaccine Targeting HPV Type 16 E5 Protein
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tumor formation.
36 The viral particles, composed
of major (L1) and minor (L2) capsids, access the
target cells and facilitate the entry of the viral
DNA, probably following minor local trauma.
Subsequent viral protein expression correlates
with differentiation in the spinous layers. Initially,
the immediate early proteins E1, E2 and E5 can
be detected. Each E1 and E2 ORF encodes DNA-
binding proteins which are required for main-
taining a stable viral episome. The E2 is involved
in the positive and negative regulation of viral
gene expression through a specific interaction
with the early promoter found in the upstream
regulatory region. In the lower spinous layers, the
E6 and E7 proteins are also expressed with the
other early proteins. They regulate cell prolifera-
tion and interfere with the host cell cycle control
mechanisms to activate cellular DNA synthesis.
This appears to be essential for viral vegetative
DNA replication. In the upper spinous layers,
vegetative DNA amplification and virus assembly
occurs with the L1 and L2 protein expression.
Although the E4 is encoded within the early
region, it is also largely restricted to the upper spi-
nous layers.
37 The precise role of E4 is unknown,
however, it is known to interact with the keratin
intermediate filaments in cultured epithelial cells.
Mature virions are released from exfoliating cells.
In HPV types associated with a malignant trans-
formation, it is clear that E6 and E7 are the
predominant transforming proteins, although E5
can also show oncogenic potential. The major
mechanism by which oncogenic HPV E6 and E7
contribute to the development of cervical cancers
is due to a functional interaction with p53 and Rb,
respectively. These proteins play a pivotal role in
the negative regulation of the growth. The E6
from oncogenic HPVs binds to p53 with high
affinity, resulting in a loss of p53-dependent func-
tions including G1 arrest and apoptosis.
38 The
consequence of E7 binding to Rb is to prevent Rb
binding to and sequestration of E2F transcription
factors, leading to a disruption of the cell cycle
control.
39 In the initial infection, HPV is present as
an episome. However, in the majority of more
advanced lesions and invasive tumors, HPV is
integrated into the host genome. The E6/E7 tran-
scripts from integrated HPV genomes have in-
creased stability as compared with episomally
derived viral mRNA, and there is an increased
expression in more severe lesions and cancers.
This may result from a disruption of the E2 gene
during integration. Following integration, viral
particles can no longer be produced, but con-
tinued E6 and E7 activity prolongs the cell cycle,
leading to the loss of effective DNA repair mecha-
nisms. This provides opportunity for the accumu-
lation of genetic changes in a multi-step process
that result in the development of cancer. There-
fore, numerical and structural chromosomal
changes in cervical cancer are common, and allelic
losses have been observed in many different
chromosomal regions.
40 The E5 is expressed in
earlier stages of neoplastic transformation on
cervical epithelia during viral infection. Since
early lesions usually contain fewer tumor cells, a
host immune response may have a higher chance
to eradicate tumor cells by tumor-specific cyto-
toxic T lymphocytes (CTL) in premalignant
lesions than in invasive cervical cancers (Fig. 4).
OTHER ONCOGENIC VIRAL PROTEINS, E6
AND E7
HPV-16 E6 protein
The HPV-16 E6 protein is a 151-amino acid pro-
tein, containing two zinc finger domains. The E6
induces several important changes in a host cell
that impact both the normal viral life cycle and
the process of immortalization. The E6 alone is not
capable of immortalizing primary human foreskin
keratinocytes (HFK), but can efficiently immor-
talize human mammary epithelial cells (HMEC).
9
However, the E6 acts with the E7 to immortalize
HFK. Expression of the E6 as a transgene in mice
leads to hyper-proliferation of epithelial layers,
loss of differentiation in epithelial layers, and
formation of benign and malignant tumors. The
E6 is one of the earliest expressed genes during
the HPV infection. It alters the cellular environ-
ment and confers it more amenable to production
of new viral particles. This includes blocking
apoptosis through p53 degradation,
41 altering
transcription of cellular genes through interaction
with p300, and increasing cellular lifespan
through increased telomerase activity.
42 TheseSang-Woo Kim and Joo-Sung Yang
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functions serve to facilitate the viral life cycle.
HPV-16 E7 protein
The HPV E7 ORF has the major transforming
activity. The HPV-16 E7 is a nuclear protein of 98
amino acids with casein kinase II phosphorylation
sites at serine residues 31 and 32.
43 The protein is
divided into domains based upon homology to
the adenovirus E1A. The domains are: CR1 con-
sisting of amino acids 1-20, CR2 containing
residues 21-39 and CR3 composed of amino acids
40-98. The E7 dimerizes via a zinc-finger motif in
the CR3 region essential for proper protein
folding. Numerous interactions between E7 and
cellular proteins have been described.
9 Many of
these interactions involve factors regulating cell
growth, especially the transition from the G1 to
S-phase in the mitotic cycle. The E7 protein has
been demonstrated to be associated with the
retinoblastoma tumor suppressor protein family
(Rb, p107, p130), histone deacetylases (HDAC),
AP-1 transcription factors, cyclins, Cdks and cdk
inhibitors.
44 These associations likely contribute to
the ability of the E7 to induce cellular prolifera-
tion, immortalization and transformation.
CURRENT HPV VACCINES
The well-defined virologic, genetic and patholo-
gical progression information on HPV, from initial
infection to lesion formation to malignant tumor
formation, and the limited number of well-defined
viral antigens, provide unique opportunities to
evaluate interventions with antigen-specific im-
munotherapy at various stages of HPV infection
and tumorigenesis. Conceptually, two different
types of HPV vaccines can be designed, one for
prophylactic (preventive) vaccines preventing
HPV infection and the other for therapeutic (cura-
tive) vaccines inducing regression of established
HPV infection and its sequelae.
Fig. 4. Host immune response to early HPV infection. The HPV infects the basal/suprabasal keratinocyte. The infected
cell is proliferated and transformed by the E5 protein. This cell is in the premalignant stage. The E5 protein ( ) is
presented by MHC class I and class II. CD4
+ T-cells recognize the presented E5 antigenic epitope and are activated. The
activated CD4
+ T-cells activate CD8
+ T-cells resulting in differentiation to the E5-specific CTL. This CTL specifically kills
the E5 presenting premalignant cells.Therapeutic Vaccine Targeting HPV Type 16 E5 Protein
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Prophylactic HPV vaccines
Prophylactic HPV vaccine development has
been complicated by the lack of animal models for
the genital mucosatropic HPV types and by dif-
ficulty in propagating the virus in culture. These
difficulties have been partially overcome by using
cutaneous and mucosal administration of animal
papillomaviruses and by the development of
virus-like particles (VLPs) and pseudovirions.
45
Yet, these models do not adequately simulate
sexual transmission. When the papillomavirus
major capsid protein L1 is over-expressed in
mammalian, insect, yeast or bacterial cells, capso-
meres are spontaneously assembled to form VLPs
which are devoid of the oncogenic viral genomes.
Parenteral injection of these VLPs elicits high
titers of serum-neutralizing antibodies and pro-
tective immunity, as shown from several animal
papillomavirus model systems with experimental
challenge of infectious virus. Although VLP
vaccination provides a host immunity from the
experimental inoculation, it is unclear whether
this extends to protection against natural trans-
mission of genital HPV.
46 To completely prevent
sexual transmission of genital HPV infection,
neutralizing antibodies must act at mucosal
surfaces, which are the natural site of infection.
47
Antibodies are produced by the plasma B cell
passing into genital secretions and by local plasma
cells. The plasma cell precursors which migrate to
the genital tract are derived primarily from
mucosal lymphoid tissues and predominantly
secrete IgA. Induction of these cells requires direct
immunization of the mucosa-associated lymphoid
tissue. In several experimental systems, nasal in-
stillation was found to be the most effective
method of immunization to generate specific
antibodies in genital secretions in mice and
monkeys. More recently, oral vaccination with the
HPV VLPs in mice has been shown to induce
systemic virus-neutralizing antibodies, suggesting
that the HPV VLPs may be antigenically stable in
the environment of the gastrointestinal tract.
These studies provide the possibility of vacci-
nating large populations with the HPV VLP with-
out using syringes. Local, sustained production of
secretory IgA and/or specific IgG is likely re-
quired for long-lasting sterilizing immunity. In
previous studies, systemic immunization of mice
with the purified HPV VLPs induced no detec-
table mucosal IgA antibodies and low titers of
IgG. Furthermore, low titers of VLP-specific IgG,
and no IgA, were detected in cervicovaginal
lavage of parenterally immunized monkeys.
48
Nasal immunization using HPV-16 VLPs has been
shown to induce significant and sustained titers of
HPV-16 neutralizing antibodies in both serum and
mucosal secretions of mice. The promising results
generated in preclinical animal studies have led to
phase I/II clinical trials using the HPV-16 VLP
vaccine delivered intramuscularly. Recently, Liu
et al.
49 showed that the HPV-16 L1 protein could
be expressed in transgenic tobacco plants and that
the expressed protein possessed the natural
features of the HPV-16 L1 protein, implying that
the HPV-16 L1 transgenic plants could potentially
be used as an edible vaccine. These studies sug-
gest the possibility of vaccinating large popula-
tions with the HPV VLPs without using syringes.
In recent clinical data, intramuscular vaccination
of women with the HPV-16 VLPs was found to
induce significant antibody titers in cervical
secretions.
50 A comparison of nasal spray versus
aerosol for mucosal delivery of 50 g of HPV-16 μ
VLPs to humans revealed that aerosol was more
effective for inducing an antibody response, with
IgG found predominantly in serum and both IgG
and IgA found in cervical secretions. A recent
clinical trial of HPV-16 L1 VLPs shows for the first
time that a vaccine strategy could be implemented
in humans to prevent HPV-16 infection and HPV-
16-associated premalignant lesions.
51 Taken to-
gether, using VLPs for prophylactic vaccination
prevents HPV infection and disease.
Therapeutic HPV vaccines
The development of a second-generation vac-
cine that will provide a T-cell response to elimi-
nate infected cells is promising. Therapeutic vac-
cines should induce specific cell-mediated immu-
nity which prevents the development of lesions
and eliminates pre-existing lesions or even malig-
nant tumors. Theoretically, the induced antigen
(Ag)-specific cellular immunity can directly target
HPV viral gene products, the HPV-induced cel-
lular products, or a combination of both. The L1Sang-Woo Kim and Joo-Sung Yang
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and L2 capsid proteins are unlikely to be suitable
targets for therapeutic vaccine development
because these proteins are not detectably ex-
pressed in basal epithelial cells of benign lesions
or in abnormal proliferative cells of premalignant
and malignant lesions.
3 Although a previous
study indicated that vaccination with VLPs may
generate a capsid protein-specific CTL response,
such a response against L1 or L1/ L2 VLPs alone
would not likely result in a significant therapeutic
effect.
52 Since E6 and E7 are consistently expressed
in most cervical cancers and their precursor
lesions, but are absent from normal tissues, these
viral oncoproteins represent promising targets for
the development of Ag-specific therapeutic vac-
cines for HPV-associated cervical malignancies
and their precursor lesions. While most tumor-
specific Ags are derived from normal or mutated
proteins, E6 and E7 are completely foreign viral
proteins. Therefore, these proteins harbor more
antigenic peptides/epitopes than an altered cel-
lular protein. Furthermore, since E6 and E7 are
required for the induction and maintenance of the
malignant phenotype of cancer cells, cervical can-
cer cells are unlikely to evade an immune re-
sponse through Ag loss.
53 Studies using modified
adenovirus (AdV)-expressing HPV-16 E6 or E7 for
vaccination or for ex vivo preparation of dendritic
cell (DC)-based vaccines have demonstrated an
enhancement of Ag-specific T-cell immune re-
sponses and anti-tumor effects.
54 A replication-
defective adeno-associated virus (AAV) encoding
HPV-16 E7 fused to heat-shock protein 70 was
found to induce CD4- and CD8-dependent CTL
activity and anti-tumor effects in vitro.
55 Peptide
vaccines have the advantage of safety and ease of
production, however, their weak immunogenic
properties and the need for human leukocyte an-
tigen (HLA) matching must be overcome. Because
40% of Caucasians carry the HLA-A2 alleles,
HPV-16 E7 peptides presented by this allele have
been the immunogen in several phase I/II clinical
trials.
56 Whereas peptide vaccines exhibit MHC
restriction, protein-based vaccines can bypass this
restriction and thus are less dependent on the
patient's HLA type. The HPV-6 L2 fused to the E7
protein has been successfully tested for the clinical
treatment of genital warts.
57 The potency of HPV-
16 E7 peptide-based vaccines may be further en-
hanced through the use of adjuvants, fusion
proteins, or anchor-modified peptide epitopes.
Chu et al.
58 demonstrated that adjuvant-free
immunization of C57B1/6 mice with heat shock
protein E7 (hspE7) protected the animals against
challenge with an E7-expressing murine tumor
cell line (TC-1), and also protected against a re-
challenge with higher doses of TC-1 cells. Simi-
larly, immunization of tumor-bearing mice with
hspE7 led to tumor regression, protection from
re-challenge and long-term survival. Tumor re-
gression after hspE7 immunization appeared to be
dependent on CD8
+ T-cell activity but indepen-
dent of CD4
+ T-cells. More recently, in a single-
stage phase II study, DNA vaccines allowed for
sustained antigen presentation as MHC-peptide
complexes as compared with peptide or protein
vaccines.
59 Due to the weak intrinsic potency of
naked DNA vaccines, various strategies have been
developed to enhance their immunogenicity. To
this end, recent research has used a method to
prolong in vivo DC survival. Co-administration of
the E7-containing DNA with anti-apoptotic pro-
teins (Bcl-xl, Bcl-2) enables the DNA vaccine to
enhance E7-specific immune responses, tumor
treatment and DC survival.
59 The DCs are the
most potent antigen presenting cells (APCs) in the
immune system and techniques have been devel-
oped for isolation, cultivation and Ag loading on
MHC of DC. Santin et al.
60 demonstrated that
recombinant, full-length, E7-pulsed, autologous
DCs could elicit a specific CD8
+ CTL response
against autologous tumor target cells in three
patients with HPV-16 or HPV-18-positive cervical
cancer. Their results demonstrated that full-length,
E7-pulsed DCs could induce both E7-specific
CD4
+ T-cell proliferative responses and strong
CD8
+ CTL responses capable of killing autologous
HPV-infected cancer cells in cervical cancer
patients. Transduction of tumor cells with genes
encoding co-stimulatory molecules or cytokines
may enhance immunogenicity, leading to T-cell
activation and anti-tumor effects after vaccination.
Vaccines using HPV-transformed tumor cells
transfected with cytokine genes, such as inter-
leukin (IL)-12, IL-2, or granulocyte macrophage-
colony stimulating factor (GM-CSF), can generate
strong anti-tumor effects in mice.
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HPV vaccines targeting E5
The E5 is expressed in precancerous stages of
cervical epithelium during HPV infection. Since
precancerous lesions usually contain fewer cells
than the invasive malignancies, it can be spe-
culated that early immunological intervention
might offer a chance to eradicate tumors more
efficiently while still in a premalignant stage.
Furthermore, cells in more advanced stages are
found to have very low expression levels of MHC
class I and II mRNA, which may consequently
hamper the presentation of tumor Ag and lead to
decreased immunosurveillance. Some reports de-
monstrated that lymphocyte proliferation in
response to the HPV-16 E5 is inversely propor-
tional to the severity of the squamous intraepi-
thelial neoplasia lesions (SILs).
61 Hence, in the
E5-expressed precancerous lesions such as SILs
and condyloma, using E5 as a vaccine target
might be a reasonable strategy to prevent these
from progression toward invasive cervical
cancers. One investigation demonstrated that a
single muscular injection of recombinant AdV
encoding the HPV-16 E5 gene into mice with a
TC-1 tumorigenic stable cell line engineered to
express the E5 protein could reduce tumor growth
in the lesions containing the E5 gene.
62 The po-
tency of the E5 vaccine might be exerted via CD8
+
rather than CD4
+ T-cells. This indicates that the E5
might be identified as a tumor Ag by the immune
system. Recently, HPV-16 E5 25-33 peptide plus
CpG oligodeoxynucleotides (ODN) was shown to




The HPV type 16 is the predominant type of
virus identified in cervical cancers. It encodes
three transforming oncogenes, E5, E6, and E7. The
HPV genomes are commonly found to be inte-
grated into the host genome. Therefore, the E6/E7
genes remain intact in the host genome, E5 is lost
or, if present, under-expressed as compared with
E6/E7. This suggests that E5 may play a critical
role in the genesis of cervical cancer but less of
a role in its persistence or progression. The E5, E6,
and E7 are unique tumor Ags and may serve as
ideal Ags to be targeted as a tumor vaccine. Most
of the evidence for HPV Ag-directed immuno-
therapy against cervical cancer comes from the
experimental and natural papillomavirus-asso-
ciated tumors that can be controlled by immu-
nization with E6/E7 Ags. In this review paper, we
address the potential of the E5 protein as a tumor
Ag inducing E5-specific CD8
+ T-cells to eradicate
tumor growth. In vivo studies demonstrate E5
expression soon after infection, with both mRNA
and protein detectable in low-grade squamous
intraepithelial lesions. The prevalence of E5
mRNA is increased with progressing severity of
the disease. Therefore, when E5 is expressed in
earlier stages of neoplastic transformation of the
cervical epithelium due to viral infection, the early
lesions usually contain fewer tumor cells. The
immune effector cells in premalignanant lesions
may eradicate tumor cells more efficiently than in
the invasive cervical cancers. The CTL activated
by the E5 protein will effectively kill tumor cells.
Therefore, the E5 is a better target gene than other
HPV-16 genes to eliminate tumor cells in the early
onset stages of the disease.
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